In his weekly clinical update, Dr. Griffin discusses a microbiologist who was harassed during COVID pandemic sues university, use of inactivated poliovirus vaccine for poliovirus outbreak response, safety and immunogenicity of bivalent rsvpref vaccine coadministered with seasonal inactivated influenza vaccine in older adults, coffee as a dietary strategy to prevent SARS-CoV-2 infection, enrollment of pediatric patients in COVID-19 interventional trials, vaccination, immunity, and the changing impact of COVID-19 on infant health, COVID-19 vaccine effectiveness against post- COVID -19 condition among 589722 individuals in Sweden, repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting, protection conferred by COVID-19 vaccination, prior SARS-CoV-2 infection, or hybrid immunity against Omicron-associated severe outcomes among community-dwelling adults, the Novavax heterologous COVID booster demonstrates lower reactogenicity than mRNA vaccines, T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19, oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China, and how COVID-19 convalescent plasma therapy decreases inflammatory cytokines, therapeutic heparin in non-ICU patients hospitalized for COVID-19 in the ACTIV-4a trial.

Anthony writes: Hi Twiv Team,  Recently I came across a news article discussing how the second person to ever receive a heart transplant from a genetically modified pig died 2 months post-surgery. This got me…

Vincent travels to the University of Vermont to speak with Jason, Emily, Jessica, and Dimitry about their careers and their work on SARS-CoV-2, hantaviruses, poliovirus, influenza virus, and the involvement of viruses in the autoimmune disease multiple sclerosis.

Nicole writes: Hello, My name is Nicole and I am a big fan of all the microbe.tv podcasts and have been for years! I am currently writing a thesis proposal on WNV and remembered hearing…

In his weekly clinical update, Dr. Griffin discusses modeling poliovirus transmission and responses in New York State, FDA approves first vaccine for pregnant individuals to prevent RSV in infants, prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Cmmittee on Immunization Practices, Nirmatrelvir resistance – de novo E166V/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir/ritonavir monotherapy leading to clinical and virological treatment failure, incidence of new-onset hypertension post–COVID-19: comparison with influenza, and post-acute sequelae of COVID-19 at 2 years.

Carl writes: The major pre-existing antibody of concern in factor eight gene therapy is anti-factor eight antibodies. Antibodies against the virus are much more rare. This gene therapy would probably be ineffective if the patient…

Tom writes: Dear TWIV team, Thank you for all you do in educating the public – scientists and non-scientists alike.    I came across an interesting paper – “A common allele of HLA is associated with…

Alice writes: Hi Dr. Griffin, I found your podcast really interesting and it raised 2 questions for me: I am 79 and reasonably healthy (with SVT).  I had a bivalent booster in October ’22 which…